Skip to main content
Erschienen in: Archives of Virology 7/2010

01.07.2010 | Original Article

Immune response to fused core protein of hepatitis C virus and truncated tetanus toxin peptides in mice

verfasst von: Xing-bin Hu, Qiao-hong Yue, Hai-feng Ouyang, Yao-zhen Chen, Xue-qing Xu, Wen Yin, San-hua Wei, Xian-qing Zhang, Shi-jie Mu

Erschienen in: Archives of Virology | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Because no vaccine or effective therapy is available, thousands of people with HCV have died in recent years. Cytotoxic T lymphocytes (CTLs) play a critical role in the host cellular immune response against HCV. CTL epitopes in HCV core protein have been identified and used in vaccine development. T helper epitopes could promote cytokine secretion and antibody production to fight HCV. Tetanus toxin, an immunogen with many T helper epitopes, was once used in HBV therapeutic vaccine design. Here, eukaryotic and prokaryotic expression vectors were constructed to express truncated fragments of tetanus toxin and core genes of HCV. HLAA2.1 transgenic mice were inoculated with a recombinant plasmid vehicle with these two heterogenic gene fragments, and this augmented the titres of antibody against HCV. Antigen-specific lymphocyte proliferation, Th1 and Th2 cytokine levels and the number of lysed cells were markedly increased in the combined immunization group compared to controls. These findings provide new insights into a potential role for T helper epitopes from tetanus toxin combined with protein from the HCV core gene, which has numerous CTL epitopes. This design strategy may aid in the development of new vaccines against HCV.
Literatur
1.
Zurück zum Zitat Acosta-Rivero N, Duenas-Carrera S, Alvarez-Lajonchere L, Morales-Grillo J (2004) HCV core protein-expressing DNA vaccine induces a strong class I-binding peptide DTH response in mice. Biochem Biophys Res Commun 314:781–786CrossRefPubMed Acosta-Rivero N, Duenas-Carrera S, Alvarez-Lajonchere L, Morales-Grillo J (2004) HCV core protein-expressing DNA vaccine induces a strong class I-binding peptide DTH response in mice. Biochem Biophys Res Commun 314:781–786CrossRefPubMed
2.
Zurück zum Zitat Alekseeva E, Sominskaya I, Skrastina D, Egorova I, Starodubova E, Kushners E, Mihailova M, Petrakova N, Bruvere R, Kozlovskaya T, Isaguliants M, Pumpens P (2009) Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen. Genet Vaccines Ther 7:7CrossRefPubMed Alekseeva E, Sominskaya I, Skrastina D, Egorova I, Starodubova E, Kushners E, Mihailova M, Petrakova N, Bruvere R, Kozlovskaya T, Isaguliants M, Pumpens P (2009) Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen. Genet Vaccines Ther 7:7CrossRefPubMed
3.
Zurück zum Zitat Alvarez-Lajonchere L, Shoukry NH, Gra B, Amador-Canizares Y, Helle F, Bedard N, Guerra I, Drouin C, Dubuisson J, Gonzalez-Horta EE, Martinez G, Marante J, Cinza Z, Castellanos M, Duenas-Carrera S (2009) Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 16:156–167CrossRefPubMed Alvarez-Lajonchere L, Shoukry NH, Gra B, Amador-Canizares Y, Helle F, Bedard N, Guerra I, Drouin C, Dubuisson J, Gonzalez-Horta EE, Martinez G, Marante J, Cinza Z, Castellanos M, Duenas-Carrera S (2009) Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 16:156–167CrossRefPubMed
4.
Zurück zum Zitat Aronsohn A, Reau N (2009) Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol 43:661–671CrossRefPubMed Aronsohn A, Reau N (2009) Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol 43:661–671CrossRefPubMed
5.
Zurück zum Zitat Bar-On ES, Goldberg E, Fraser A, Vidal L, Hellmann S, Leibovici L (2009) Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Database Syst Rev 3:1469–1493 Bar-On ES, Goldberg E, Fraser A, Vidal L, Hellmann S, Leibovici L (2009) Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Database Syst Rev 3:1469–1493
6.
Zurück zum Zitat Bolhassani A, Ghasemi N, Servis C, Taghikhani M, Rafati S (2009) The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen. Drug Deliv 16:196–204CrossRefPubMed Bolhassani A, Ghasemi N, Servis C, Taghikhani M, Rafati S (2009) The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen. Drug Deliv 16:196–204CrossRefPubMed
7.
8.
Zurück zum Zitat Dustin LB, Rice CM (2007) Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 25:71–99CrossRefPubMed Dustin LB, Rice CM (2007) Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 25:71–99CrossRefPubMed
9.
Zurück zum Zitat Fujino T, Nakamuta M, Aoyagi Y, Fukuizumi K, Takemoto R, Yoshimoto T, Miyahara T, Harada N, Sakai H, Nakashima M, Enjoji M (2009) Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy. J Dig Dis 10:21–25CrossRefPubMed Fujino T, Nakamuta M, Aoyagi Y, Fukuizumi K, Takemoto R, Yoshimoto T, Miyahara T, Harada N, Sakai H, Nakashima M, Enjoji M (2009) Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy. J Dig Dis 10:21–25CrossRefPubMed
10.
Zurück zum Zitat Guglietta S, Garbuglia AR, Salichos L, Ruggeri L, Folgori A, Perrone MP, Camperio C, Mellace V, Maio G, Maio P, Capobianchi MR, Spada E, Gargano N, Scotta C, Piccolella E, Del Porto P (2009) Impact of viral selected mutations on T cell mediated immunity in chronically evolving and self limiting acute HCV infection. Virology 386:398–406CrossRefPubMed Guglietta S, Garbuglia AR, Salichos L, Ruggeri L, Folgori A, Perrone MP, Camperio C, Mellace V, Maio G, Maio P, Capobianchi MR, Spada E, Gargano N, Scotta C, Piccolella E, Del Porto P (2009) Impact of viral selected mutations on T cell mediated immunity in chronically evolving and self limiting acute HCV infection. Virology 386:398–406CrossRefPubMed
11.
Zurück zum Zitat Hewlett AT (2009) Combined hepatitis A and B vaccine: providing a bright future for preventing hepatitis. Expert Opin Biol Ther 9:1235–1240 Hewlett AT (2009) Combined hepatitis A and B vaccine: providing a bright future for preventing hepatitis. Expert Opin Biol Ther 9:1235–1240
12.
Zurück zum Zitat Iwasa M, Hara N, Miyachi H, Tanaka H, Takeo M, Fujita N, Kobayashi Y, Kojima Y, Kaito M, Takei Y (2009) Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels. J Viral Hepat 16:716–723 Iwasa M, Hara N, Miyachi H, Tanaka H, Takeo M, Fujita N, Kobayashi Y, Kojima Y, Kaito M, Takei Y (2009) Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels. J Viral Hepat 16:716–723
13.
Zurück zum Zitat Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW (2002) Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 123:1070–1083CrossRefPubMed Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW (2002) Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 123:1070–1083CrossRefPubMed
14.
Zurück zum Zitat Kang M, Nicolay U (2008) Evaluation of operational chronic infection endpoints for HCV vaccine trials. Contemp Clin Trials 29:671–678CrossRefPubMed Kang M, Nicolay U (2008) Evaluation of operational chronic infection endpoints for HCV vaccine trials. Contemp Clin Trials 29:671–678CrossRefPubMed
15.
Zurück zum Zitat Klebl BM, Kurtenbach A, Salassidis K, Daub H, Herget T (2005) Host cell targets in HCV therapy: novel strategy or proven practice? Antivir Chem Chemother 16:69–90PubMed Klebl BM, Kurtenbach A, Salassidis K, Daub H, Herget T (2005) Host cell targets in HCV therapy: novel strategy or proven practice? Antivir Chem Chemother 16:69–90PubMed
16.
Zurück zum Zitat Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A (2001) Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19:4652–4660CrossRefPubMed Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A (2001) Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19:4652–4660CrossRefPubMed
17.
Zurück zum Zitat Newberg MH, Smith DH, Haertel SB, Vining DR, Lacy E, Engelhard VH (1996) Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J Immunol 156:2473–2480PubMed Newberg MH, Smith DH, Haertel SB, Vining DR, Lacy E, Engelhard VH (1996) Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J Immunol 156:2473–2480PubMed
18.
Zurück zum Zitat Niu Y, Komatsu N, Komohara Y, Matsueda S, Yutani S, Ishihara Y, Itou M, Yamada A, Itoh K, Shichijo S (2009) A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA alleles. J Med Virol 81:1232–1240CrossRefPubMed Niu Y, Komatsu N, Komohara Y, Matsueda S, Yutani S, Ishihara Y, Itou M, Yamada A, Itoh K, Shichijo S (2009) A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA alleles. J Med Virol 81:1232–1240CrossRefPubMed
19.
Zurück zum Zitat Park SH, Lee SR, Hyun BH, Kim BM, Sung YC (2008) Codelivery of PEG-IFN-alpha inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys. Vaccine 26:3978–3983CrossRefPubMed Park SH, Lee SR, Hyun BH, Kim BM, Sung YC (2008) Codelivery of PEG-IFN-alpha inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys. Vaccine 26:3978–3983CrossRefPubMed
20.
21.
Zurück zum Zitat Semmo N, Day CL, Ward SM, Lucas M, Harcourt G, Loughry A, Klenerman P (2005) Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 41:1019–1028CrossRefPubMed Semmo N, Day CL, Ward SM, Lucas M, Harcourt G, Loughry A, Klenerman P (2005) Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 41:1019–1028CrossRefPubMed
22.
Zurück zum Zitat Shi TD, Wu YZ, Jia ZC, Zou LY, Zhou W (2004) Therapeutic polypeptides based on HBV core 18–27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs. World J Gastroenterol 10:1902–1906PubMed Shi TD, Wu YZ, Jia ZC, Zou LY, Zhou W (2004) Therapeutic polypeptides based on HBV core 18–27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs. World J Gastroenterol 10:1902–1906PubMed
23.
Zurück zum Zitat Snyder JT, Belyakov IM, Dzutsev A, Lemonnier F, Berzofsky JA (2004) Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J Virol 78:7052–7060CrossRefPubMed Snyder JT, Belyakov IM, Dzutsev A, Lemonnier F, Berzofsky JA (2004) Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J Virol 78:7052–7060CrossRefPubMed
24.
Zurück zum Zitat Thimme R, Lohmann V, Weber F (2006) A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res 69:129–141CrossRefPubMed Thimme R, Lohmann V, Weber F (2006) A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res 69:129–141CrossRefPubMed
25.
Zurück zum Zitat Wan L, Kung YJ, Lin YJ, Liao CC, Sheu JJ, Tsai Y, Lai HC, Peng CY, Tsai FJ (2009) Th1 and Th2 cytokines are elevated in HCV-infected SVR(−) patients treated with interferon-alpha. Biochem Biophys Res Commun 379:855–860CrossRefPubMed Wan L, Kung YJ, Lin YJ, Liao CC, Sheu JJ, Tsai Y, Lai HC, Peng CY, Tsai FJ (2009) Th1 and Th2 cytokines are elevated in HCV-infected SVR(−) patients treated with interferon-alpha. Biochem Biophys Res Commun 379:855–860CrossRefPubMed
26.
Zurück zum Zitat Wang YC, Hu XB, He F, Feng F, Wang L, Li W, Zhang P, Li D, Jia ZS, Liang YM, Han H (2009) Lipopolysaccharide-induced maturation of bone marrow-derived dendritic cells is regulated by notch signaling through the up-regulation of CXCR4. J Biol Chem 284:15993–16003CrossRefPubMed Wang YC, Hu XB, He F, Feng F, Wang L, Li W, Zhang P, Li D, Jia ZS, Liang YM, Han H (2009) Lipopolysaccharide-induced maturation of bone marrow-derived dendritic cells is regulated by notch signaling through the up-regulation of CXCR4. J Biol Chem 284:15993–16003CrossRefPubMed
27.
Zurück zum Zitat Wei SH, Yin W, An QX, Lei YF, Hu XB, Yang J, Lu X, Zhang H, Xu ZK (2008) A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen. Arch Virol 153:1021–1029CrossRefPubMed Wei SH, Yin W, An QX, Lei YF, Hu XB, Yang J, Lu X, Zhang H, Xu ZK (2008) A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen. Arch Virol 153:1021–1029CrossRefPubMed
28.
Zurück zum Zitat White C, Halperin SA, Scheifele DW (2009) Pediatric combined formulation DTaP-IPV/Hib vaccine. Expert Rev Vaccines 8:831–840CrossRefPubMed White C, Halperin SA, Scheifele DW (2009) Pediatric combined formulation DTaP-IPV/Hib vaccine. Expert Rev Vaccines 8:831–840CrossRefPubMed
30.
Zurück zum Zitat Wolters B, Muller T, Ross RS, Clauberg R, Werfel U, Roggendorf H, Siggelkow C, Hausen T, Roggendorf M (2009) Comparative evaluation of the immunogenicity of combined hepatitis A and B vaccine by a prospective and retrospective trial. Hum Vaccin 5:248–253 Wolters B, Muller T, Ross RS, Clauberg R, Werfel U, Roggendorf H, Siggelkow C, Hausen T, Roggendorf M (2009) Comparative evaluation of the immunogenicity of combined hepatitis A and B vaccine by a prospective and retrospective trial. Hum Vaccin 5:248–253
31.
Zurück zum Zitat Yang M, Zhu F, Sonderstrup G, Eckels DD (2005) Recognition of endogenously synthesized HLA-DR4 restricted HCV epitopes presented by autologous EBV transformed B-lymphoblastoid cell line. Vaccine 23:951–962CrossRefPubMed Yang M, Zhu F, Sonderstrup G, Eckels DD (2005) Recognition of endogenously synthesized HLA-DR4 restricted HCV epitopes presented by autologous EBV transformed B-lymphoblastoid cell line. Vaccine 23:951–962CrossRefPubMed
32.
Zurück zum Zitat Yue Q, Hu X, Yin W, Xu X, Wei S, Lei Y, Lu X, Yang J, Su M, Xu Z, Hao X (2007) Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice. J Virol Methods 141:41–48CrossRefPubMed Yue Q, Hu X, Yin W, Xu X, Wei S, Lei Y, Lu X, Yang J, Su M, Xu Z, Hao X (2007) Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice. J Virol Methods 141:41–48CrossRefPubMed
33.
Zurück zum Zitat Zeng R, Li G, Ling S, Zhang H, Yao Z, Xiu B, He F, Huang R, Wei L (2009) A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice. Antiviral Res 84:23–30CrossRefPubMed Zeng R, Li G, Ling S, Zhang H, Yao Z, Xiu B, He F, Huang R, Wei L (2009) A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice. Antiviral Res 84:23–30CrossRefPubMed
Metadaten
Titel
Immune response to fused core protein of hepatitis C virus and truncated tetanus toxin peptides in mice
verfasst von
Xing-bin Hu
Qiao-hong Yue
Hai-feng Ouyang
Yao-zhen Chen
Xue-qing Xu
Wen Yin
San-hua Wei
Xian-qing Zhang
Shi-jie Mu
Publikationsdatum
01.07.2010
Verlag
Springer Vienna
Erschienen in
Archives of Virology / Ausgabe 7/2010
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-010-0692-2

Weitere Artikel der Ausgabe 7/2010

Archives of Virology 7/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.